DiaSorin S.p.A. (DSRLF) Q3 2023 Earnings Call Transcript


DiaSorin S.p.A. (OTCPK:DSRLF) Q3 2023 Earnings Conference Call November 3, 2023 11:30 AM ET

Company Participants

Carlo Rosa – Chief Executive Officer

Piergiorgio Pedron – Chief Financial Officer

Conference Call Participants

Odysseas Manesiotis – Berenberg

Maja Pataki – Kepler Cheuvreux

Aisyah Noor – Morgan Stanley

Operator

Good afternoon. This is the Chorus Call Conference operator. Welcome, and thank you for joining the DiaSorin Nine Months 2023 Results Conference Call. As a reminder, all participants are in a listen-only mode. After the presentation, there will be an opportunity to ask questions. [Operator Instructions]

At this time, I would like to turn the conference over to Mr. Carlo Rosa, CEO of DiaSorin. Please go ahead.

Carlo Rosa

Thank you, operator. And good morning, good afternoon. And welcome to the Q3 Conference Call. As usual, I am going to give some comments at constant exchange rate about three legs of the business. The Immunodiagnostics, Molecular Diagnostics and Licensed Technologies. And then I will let our CFO go through the numbers. So if we start from the overall results, the quarter was in line with the expectation. Growth excluding COVID at constant exchange rate, it was 2% in the quarter, over 3% year-to-date. So it’s in line with the guidance and the expectations. Although if we look at the three legs of the business, we have different results.

So let’s start from the Immunodiagnostics. Immunodiagnostics continues to do extremely well for the company. In Q3, growth is 6%, and has been a very strong growth in Europe and in North America and some other smaller geographies, and notwithstanding some of the weakness that we continue to experience in the Chinese market. If we look at CLIA, which is the main component of our Immunodiagnostics, overall in the quarter, plus 10%. So we continue to experience double-digit growth in our main technology. If we go now



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *